For the treatment of the following conditions:
risk of stroke and systemic embolism in non-valvular atrial
Deep Vein Thrombosis
the risk of recurrence of deep vein thrombosis and of pulmonary
embolism following initial 6 months treatment for DVT and/or
of deep vein thrombosis which may lead to PE in patients undergoing
knee or hip replacement surgery.
Rivaroxaban is an orally bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require a cofactor (such as Anti-thrombin III) for activity. Activation of factor X to factor Xa (FXa) via the intrinsic and extrinsic pathways plays a central role in the cascade of blood coagulation.
Tablet 10mg, 15mg and 20mg
10's and 14's